Antibacterial activity of TOC-50, a new parenteral cephalosporin against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
TOC-50, a new parenteral cephalosporin, was assessed for antibacterial activity in vitro and in vivo. In vitro, the activity of TOC-50 was greater than ampicillin, erythromycin and gentamycin, and was equal to that of imipenem. The MICs of TOC-50 for 90% of the clinical isolates tested (MIC90 values) were 0.0125 microgram/ml for penicillin-susceptible Streptococcus pneumoniae, 0.2 microgram/ml for intermediately penicillin-resistant S. pneumoniae, and 0.39 microgram/ml for fully penicillin-resistant S. pneumoniae. In murine systemic-infection models, TOC-50 had a potent protective activity against penicillin-susceptible of fully penicillin-resistant S. pneumoniae. Its protective activity was stronger than that of imipenem.
Nomura
S
S
Anticancer and Antimicrobial Research Laboratory, Taiho Pharmaceutical Company, Tokushima, Japan.
Hanaki
H
H
Furukawa
T
T
Unemi
N
N
D000818:Animals; D002511:Cephalosporins / Q000494:pharmacology*; D015378:Imipenem / Q000494:pharmacology; D007564:Japan; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D010400:Penicillin G / Q000494:pharmacology; D010403:Penicillin Resistance / Q000235:genetics; D010406:Penicillins / Q000494:pharmacology; D013290:Streptococcal Infections / Q000188:drug therapy; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000235:genetics; D013845:Thienamycins / Q000494:pharmacology
D002511:Cephalosporins; D010406:Penicillins; C103730:TOC 50; D013845:Thienamycins; D015378:Imipenem; D010400:Penicillin G